HK-listed Genscript Biotech unit Probio to raise $150m from Hillhouse Capital

Probio Cayman, a subsidiary of Hong Kong-listed Genscript Biotech, has entered into an agreement to raise about $150 million from private equity firm Hillhouse Capital Group, the parent firm disclosed in a filing with the Hong Kong stock exchange on Thursday.